http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100267707-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7c27b9ec61781656e6f039702fd568 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-02 |
| filingDate | 1998-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2000-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de3518f3fc7060e3f81d1c734ed0fc46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd53b7b19e567c934a036b2f4ef51d81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74940f5957ac226698e4f9ebd9370de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5e9f3ef339600ed4a65e4b6ed8a2fc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16f96966acd4d1d2657f6daa68635180 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b18274a166c5e7084d2170e508e3be29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4d967d3d8e1b2505ce726fb66b2d4de |
| publicationDate | 2000-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100267707-B1 |
| titleOfInvention | 4-Substituted-Quinoline-2-carboxylic Acid Derivatives Acting as NMDA Receptor Antagonists |
| abstract | The present invention relates to a 4-substituted-quinoline-2-carboxylic acid derivative of Formula 1, a method for preparing the same, and an antagonist having a strong and specificity that acts on a strychinine non-sensitive glycine binding site in an NMDA receptor complex. It relates to the use as. The compounds of the present invention are useful for the treatment and prevention of neurodegenerative diseases. In particular, the compounds of the present invention are useful for reducing damage to the central nervous system resulting from anemia or hypoxia such as stroke, hypoglycemia, ischemia, cardiac arrest, trauma. In addition, the compounds of the present invention are useful for the prevention and treatment of chronic neurodegenerative diseases including epilepsy, Alzheimer's disease, Huntington's disease and Parkinson's disease. In addition, the compounds of the present invention are used as anticonvulsants, analgesics, antidepressants, anti-anxiety agents and antischizophrenia.n n n [Formula 1]n n n n n n n n (R 1 and R 2 are as defined in the specification.) |
| priorityDate | 1998-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 120.